David Jack
Obesity Medicine · Draper, UTNPI 1255434296
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.7%), travel and lodging and education — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Eli Lilly at 42.2% of the total. 2022 is the largest year on record at $2,783, 2.5 times the $1,102 reported in 2019.
Across 220 payments — averaging $27.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$3K
- Amgen$511
- Novo Nordisk$305
- AbbVie$268
- Astellas Pharma US Inc$247
- Boehringer Ingelheim$208
- plus $2K from 31 others
Across 144 payments — averaging $7727.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$694K
- Eli Lilly$298K
- OPKO Pharmaceuticals, LLC$63K
- Boehringer Ingelheim$26K
- Pfizer$20K
- Boehringer Ingelheim International GmbH$6K
- plus $5K from 2 others
What the payments were for
- Speaking & faculty fees$601%
- Travel & lodging$2,42440%
- Food & beverage$3,50958%
- Education$922%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 14 | $2,571 |
| Amgen(2 entities) | 26 | $511 |
| Novo Nordisk | 24 | $305 |
| AbbVie(2 entities) | 12 | $268 |
| Astellas Pharma US Inc | 11 | $247 |
| Boehringer Ingelheim | 12 | $208 |
| Lilly USA, LLC | 16 | $186 |
| Boston Scientific | 9 | $171 |
| Amarin Pharma, Inc. | 9 | $165 |
| Sanofi-aventis U.S. LLC | 11 | $146 |
| AstraZeneca | 10 | $137 |
| GSK | 10 | $135 |
| Johnson & Johnson(2 entities) | 7 | $119 |
| Relievant Medsystems, Inc. | 1 | $96 |
| Pfizer | 7 | $94 |
| E.r. Squibb & Sons, L.L.C. | 5 | $79 |
| Sanofi | 1 | $60 |
| Abbott | 3 | $59 |
| Dexcom, Inc. | 3 | $54 |
| Novartis | 3 | $51 |
| Biogen | 3 | $48 |
| Kowa Pharmaceuticals America, Inc. | 3 | $37 |
| Mannkind Corporation | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $35 |
| Insulet Corporation | 1 | $32 |
| Merck | 2 | $29 |
| Nevro Corp. | 1 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Eisai Inc. | 2 | $27 |
| Gilead | 1 | $19 |
| Upsher-smith Laboratories LLC | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
| Dynavax Technologies Corporation | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few obesity medicine providers in Utahto place this figure against a meaningful peer group, so we don't.
Other obesity medicine in Draper
- Thomas CheckettsSalt Lake City$462
- Nicholas TrujilloLehi$121
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.